Reason for request
Extension of indication
Clinical Benefit
| Substantial |
The actual benefit of CERUBIDINE 20 mg is substantial, as part of a combination chemotherapy regimen, in the treatment of acute lymphoblastic leukaemia and acute myeloblastic leukaemia in children. |
Clinical Added Value
| no clinical added value |
CERUBIDINE 20 mg does not provide any improvement in actual benefit (level V, non-existent) in the treatment of acute lymphoblastic and myeloblastic leukaemia in children. |
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
gs6Ms4TLQGsMUtmj
